Compare ACTG & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACTG | RLMD |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.1M | 461.9M |
| IPO Year | 1995 | 2012 |
| Metric | ACTG | RLMD |
|---|---|---|
| Price | $4.36 | $3.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 164.5K | ★ 1.2M |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,004,000.00 | $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $3.22 | $1.80 |
| 52 Week High | $5.27 | $8.00 |
| Indicator | ACTG | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 31.29 |
| Support Level | N/A | $3.57 |
| Resistance Level | N/A | $4.44 |
| Average True Range (ATR) | 0.00 | 0.19 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 4.38 |
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations, and Manufacturing Operations. It derives revenue from the Intellectual Property Operations segment. Geographically, it operates in the Americas, Europe, the Middle East and Africa, China, India, and Asia-Pacific.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.